Substrate and product analogues as human O-GlcNAc transferase inhibitors by Dorfmueller, Helge C. et al.
ORIGINAL ARTICLE
Substrate and product analogues as human O-GlcNAc transferase
inhibitors
Helge C. Dorfmueller • Vladimir S. Borodkin •
David E. Blair • Shalini Pathak • Iva Navratilova •
Daan M. F. van Aalten
Received: 21 May 2010/Accepted: 1 July 2010/Published online: 17 July 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Protein glycosylation on serine/threonine resi-
dues with N-acetylglucosamine (O-GlcNAc) is a dynamic,
inducible and abundant post-translational modiﬁcation. It is
thought to regulate many cellular processes and there are
examples of interplay between O-GlcNAc and protein
phosphorylation. In metazoa, a single, highly conserved
and essential gene encodes the O-GlcNAc transferase
(OGT) that transfers GlcNAc onto substrate proteins using
UDP–GlcNAc as the sugar donor. Speciﬁc inhibitors of
human OGT would be useful tools to probe the role of this
post-translational modiﬁcation in regulating processes in
the living cell. Here, we describe the synthesis of novel
UDP–GlcNAc/UDP analogues and evaluate their inhibi-
tory properties and structural binding modes in vitro
alongside alloxan, a previously reported weak OGT
inhibitor. While the novel analogues are not active on
living cells, they inhibit the enzyme in the micromolar
range and together with the structural data provide useful
templates for further optimisation.
Keywords O-GlcNAc   Post-translational modiﬁcation  
Inhibitor   Signalling   Crystal structure
Introduction
Reversible post-translational modiﬁcation of many cyto-
plasmic and nuclear proteins in eukaryotic cells by glyco-
sylation of serine and threonine residues with b-linked
N-acetylglucosamine (O-GlcNAc) has been shown to
regulate cellular processes as diverse as transcription,
translation, insulin sensitivity, protein trafﬁcking and deg-
radation (Torres and Hart 1984; Zachara and Hart 2004;
LoveandHanover2005;Hartetal2007).Onlytwoenzymes
are responsible for the dynamic cycling of O-GlcNAc. The
O-GlcNAc transferase (OGT) transfers GlcNAc, using
UDP–GlcNAc as the sugar donor, via an inverting mecha-
nism involving as yet unidentiﬁed active site residues. The
O-GlcNAc hydrolase (OGA) cleaves the glycosidic bond,
thusreversingthemodiﬁcation.DysregulationofO-GlcNAc
is thought to play a role in human pathogenesis, such as
cancer (Chou and Hart 2001; Liu et al. 2002; Donadio et al.
2008), Alzheimer’s (Grifﬁth and Schmitz 1995; Yao and
Coleman 1998; Liu et al. 2004; Wells and Hart 2003; Dias
and Hart 2007) and diabetes (McClain et al. 2002; Copeland
et al. 2008). Hundreds of cytoplasmic and nucleoplasmic
proteins have been shown to be O-GlcNAc modiﬁed,
although the precise glycosylation sites and functional
implications have been determined for only a few of these.
Interestingly, examples of crosstalk between protein
O-GlcNAcylation and phosphorylation have been recently
reported, with the O-GlcNAcylation site being either iden-
tical or adjacent to proteinphosphorylation sites (Yang et al.
2006). However, the precise molecular mechanisms by
which OGT and OGA recognise and act on hundreds of
proteins, thereby regulating cellular signalling cascades,
remain tobe discovered(Hurtado-Guerreroetal. 2008).The
OGA enzyme has been characterised in humans, rat, Dro-
sophila andC.elegans (Kellyand Hart 1989;Dong andHart
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2006). The OGA reaction mechanism has been elucidated
and structural insights have been obtained recently from
bacterial OGAhomologues(Macauleyetal.2005;Raoetal.
2006; Dennis et al. 2006; Ficko-Blean et al. 2009). A wealth
of chemical biological tools exist to raise intracellular
O-GlcNAc levels in living cells by inhibition of O-GlcNA-
case. Until recently the only inhibitors of hOGA were the
aspeciﬁccompoundsPUGNAc(Haltiwangeretal.1998)and
streptozotocin (STZ) (Liu et al. 2000). Lately, several new
compoundshavebeendescribedthatselectivelyandpotently
inhibit human OGA (Macauley et al. 2005; Dennis et al.
2006; Dorfmueller et al. 2006; Dorfmueller et al. 2009;
Stubbs et al. 2006; Yuzwa et al. 2008). These chemical tools
are currentlyenablingstudies towards the roleof O-GlcNAc
in a range of signal transduction pathways, although it is
becomingclearthatcertaincelltypesareremarkablytolerant
of inhibitor-induced hyper-O-GlcNAcylation.
OGT was discovered ﬁrst in rat (Haltiwanger et al.
1992), subsequently in Arabidopsis thaliana (Jacobsen
et al. 1996), humans (Kreppel et al. 1997), C. elegans
(Lubas et al. 1997) and more recently in Giardia and
Cryptosporidium parvum (Banerjee et al. 2009). The gene
that encodes for human OGT (hOGT) resides on the X
chromosome and is essential for mammalian development
(Shaﬁ et al. 2000). hOGT is ubiquitously expressed, how-
ever, at particularly high levels in T cells, B cells and
macrophages, whereas lower expression levels are found in
pancreatic b-cells and the central nervous system (Hanover
et al. 2009).
The ﬁrst insights into OGT structure have recently been
obtained from an apparent bacterial OGT orthologue from
Xanthomonas campestris (XcOGT) (Clarke et al. 2008;
Martinez-Fleites et al. 2008). Structural complexes with
UDP and an UDP–GlcNAc phosphonate analogue revealed
features of the active site and three distinct domains: (1)
multiple tetratricopeptide repeats (TPRs), (2) a linker
region and (3) the catalytic (glycosyltransferase activity)
domain, belonging to the GT41 family in the CAZy data-
base (Coutinho et al. 2003). The active site is located
between the two lobes of the GT41 domain. While hOGT
mutants informed by the structural complexes (Clarke et al.
2008; Martinez-Fleites et al. 2008) have helped to identify
several inactive mutants, however, the precise catalytic
mechanism of OGT yet remains to be discovered.
The O-GlcNAc modiﬁcation is a dynamic modiﬁcation,
and thus potent and selective hOGT inhibitors would be
beneﬁcial to investigate the role of O-GlcNAc modiﬁca-
tions in signalling pathways. The ﬁrst hOGT inhibitor
reported was alloxan, an uracil analogue that is presumed
to inhibit hOGT by binding to the uracil binding pocket or
alternatively has been proposed to act through a covalent
modiﬁcation of cysteine residues (Konrad et al. 2002).
Alloxan, as a small chemical compound, is unlikely to
inhibit hOGT speciﬁcally in vivo (Zachara et al. 2004).
Furthermore, alloxan is a chemically unstable compound
with a half-life time of 1.5 min at physiological pH
(Lenzen and Munday 1991). Although alloxan inhibits
hOGT with an IC50 of 100 lM (Konrad et al. 2002), it is
required at millimolar concentrations to decrease cellular
levels of O-GlcNAcylation (Liu et al. 2005, 2006, 2007;
Noach et al. 2007; Kang et al. 2008). Recently, three novel
hOGT inhibitors were identiﬁed by high-throughput
screening (HTS) (Gross et al. 2005), although the original
report did not show that these compounds were able to
decrease global cellular O-GlcNAc levels by inhibition of
hOGT in living cells. A very recent report showed that one
of these inhibitors identiﬁed by HTS reduces O-GlcNAc
levels in MCF-10A-ErbB2 breast cancer cells when applied
at 500 lM (Caldwell et al. 2010).
Here, we report the design and evaluation of a novel
glycosyl thiophosphate analogue of UDP–GlcNAc (UDP-
S-GlcNAc) and an a,b-methylene bisphosphonate analogue
of UDP (C-UDP) as hOGT inhibitors. We have determined
inhibition constants of these compounds against hOGT and
used X-ray crystallography to demonstrate that the uridine
pyrophosphate moiety (or its mimic) occupies the nucleo-
tide sugar binding site in both cases. We have also deter-
mined the binding mode of alloxan, a widely used
(unspeciﬁc) hOGT inhibitor. Together, these compounds
and associated data form the basis for the future rational
design of more potent substrate analogue OGT inhibitors.
Materials and methods
Protein production and puriﬁcation
XcOGT wild-type (WT), mutant D471A-XcOGT and
hOGT (26-end) were expressed and puriﬁed as described
previously (Clarke et al. 2008). The proteins were con-
centrated to 10 mg/ml (XcOGT, D471A-XcOGT) and
10 lM (hOGT), respectively.
Surface plasmon resonance experiments
The molecular interaction between WT/mutant D471A-
XcOGT and nucleotide analogues were studied by surface
plasmonresonance(SPR),usingaBIAcoreT100instrument
(BiaCore, Uppsala, Sweden). WT and the D471A mutant-
XcOGT were immobilised using standard amine-coupling
chemistry in buffer consisting of 10 mM HEPES (pH 7.4)
and 150 mM NaCl. The sensor chip surface was activated at
25C with a 7 min injection of a 1:1 mixture of EDC and
NHS. Protein was injected at 0.2 mg/ml in acetate bufferpH
5.5 at a ﬂow rate of 10 ll/min for 1 min to achieve suitable
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123density of approximately 5000 RU. Finally, 1 M ethanol-
amine–HCl was injected for 7 min to deactivate the surface.
One ﬂow cell was used as a reference to subtract nonspeciﬁc
binding, drift and bulk refractive index. All experiments
were performed in 25 mM Tris–HCl (pH 7.5), and 150 mM
NaCl at 25C. Compounds were diluted in the running
buffer at a maximum concentration of 1 mM and then
threefold diluted to a concentration series ranging from
1 mM to 457 nM. Association was measured for 30 s and
dissociation for 60 s at a 30 ll/min ﬂow rate. Injections
were carried out in duplicate. Blank injections of running
bufferwereusedduringtheexperimenttocontrolthedriftof
baseline. As the experimental run time exceeded 15 h,
control injections of UDP at 100 lM were included within
the run at every eighth sample injection to detect possible
changes of activity of immobilised proteins on the surface.
Data processing and afﬁnity analysis were performed using
Scrubber 2 software (BioLogic Software). Data were cor-
rected for blank reference surface to subtract non-speciﬁc
binding and for blank buffer injections to subtract possible
drift in sensorgrams. Binding of compounds was measured
using SPR to WT-XcOGT and mutant D417A. No decrease
of response for control injections of UDP (100 lM) was
observed during the experimental run, suggesting that the
binding capacity of immobilised protein remained the same
(data not shown). Data were ﬁtted using equilibrium afﬁnity
analysis. Since most of the compound afﬁnities were in
millimolar range exceeding the highest concentration of
injected compound, the maximum binding capacity (RMAX)
could not be reached. Therefore, to calculate RMAX, UDP
was used as a control. The afﬁnity of UDP was calculated as
110 lM and reached maximum binding capacity of
approximately 36 RU. The responses for the rest of the
compounds were normalised according to their molecular
weights and ﬁtted using equilibrium ﬁt with RMAX previ-
ously calculated for UDP. In this way, binding afﬁnities
could be estimated for compounds as weak as 30 mM.
Determination of the XcOGT complex crystal structures
Puriﬁed WT-XcOGT protein was crystallised essentially as
described previously (Clarke et al. 2008). Vapour diffusion
crystallisation experiments were performed by mixing 1 ll
of XcOGT protein (10 mg/ml) and 1 ll of mother liquor
(0.1 M CHES, pH 9.5 and 25% polyethylene glycol 3350).
To obtain the XcOGT–UDP-S-GlcNAc/C-UDP and alloxan
complexes, crystals were soaked by addition of 1 llo f
20 mM UDP-S-GlcNAc/C-UDP dissolved in mother liquor
or solid alloxan. The crystals were cryoprotected by
immersion in mother liquor with increased (40%) poly-
ethylene glycol 3350 concentration. Synchrotron diffrac-
tion data were collected and processed using the HKL suite
(Pape and Schneider 2004). Reﬁnement of the ligand
complexes was initiated from the native XcOGT–UDP–
GlcNAc phosphonate structure (2JLB) (Clarke et al. 2008).
Further model building with COOT (Emsley and Cowtan
2004) and reﬁnement with REFMAC (Murshudov et al.
1997) yielded the ﬁnal models with statistics shown in
Table 3. In all three complexes, deﬁned |Fo|-|Fc|, /calc
electron density for the compounds was apparent from the
early stages of reﬁnement. Compound models were built
and reﬁned using coordinates and topologies generated by
PRODRG (Schuettelkopf and van Aalten 2004). Compar-
ison of the XcOGT–UDP-S-GlcNAc and XcOGT–alloxan
complexes with previously described XcOGT structures
(Clarke et al. 2008; Martinez-Fleites et al. 2008) shows that
there is more disorder in the N-terminal TPR domains,
which were only partially built. This is reﬂected in higher
B-factors (Table 3).
Inhibition measurements
hOGT assays were carried out at room temperature (RT) in
384-well white optiplates (Perkin Elmer). Each assay was
performed in a 20 ll reaction volume containing 50 mM
Tris buffer, pH 7.5, 2 mM dithiothreitol (DTT), 3 mM
MgCl2, 0.05 mg/ml BSA (Thermo), 0.125 lM[
3H]UDP–
GlcNAc (0.048 Ci mmol
-1) (Sigma/ARC), 1 lM biotin-
ylated DEBtide (Blair et al. manuscript submitted)
(GlycoBioChem), 50 nM hOGT and various concentra-
tions of test compounds. Test compounds were placed in
the columns 1 and 13 of a 384-well polypropylene plate
and then serially diluted in 100% DMSO through half log
increments using a JANUS 8-channel Varispan automated
workstation (PerkinElmer) to give the compound source
plate (1009 ﬁnal assay concentration). From this, 0.25 ll
of the compounds were transferred to all wells using a
Cartesian Hummingbird (Genomics Solution) before 10 ll
of either enzyme/peptide mix or peptide alone (control)
was added to the assay plates. The reaction was initiated
with 10 ll of UDP–GlcNAc and stopped after 150 min
with 40 ll of a stop solution containing 0.2 M phosphoric
acid, pH 4.0 and 1.5 M MgCl2 and 2.5 mg/ml PVT SPA
beads (GE Healthcare). All reaction mixture additions were
carried out using a Thermo Scientiﬁc WellMate (Matrix).
Plates were sealed and read on a TopCount NXT Micro-
plate Scintillation and Luminescence Counter (Perkin
Elmer). Dose–response curves were prepared and analysed
using GraFit (Leatherbarrow 2001) (Fig. 1b).
Synthesis of UDP-S-GlcNAc
Compound 2 (Fig. 1c): To a solution of 2-acetamido-2-
deoxy-3,4,6-tri-O,O,O-acetyl-1-thio-a-D-glucopyranose
(Knapp and Myers 2001)( 0 . 3 9 3g ,1 . 0 8m m o l )a n db i s ( 9 H -
ﬂuoren-9-ylmethyl)-diisopropylamidophosphite (Bialy and
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123Waldmann 2004) (0.846 g, 1.6 mmol) in MeCN (4 ml), a
stock 0.45 M solution of 1H-tetrazole (7.1 ml, 3.2 mmol)
was added at RT. After 30 min, the reaction mixture was
cooled down to -40C and a solution of dimethyldioxirane
(19 ml; 0.1 M, 1.9 mmol) was added in one portion. The
reaction mixture was further stirred for 30 min while the
temperature was allowed to reach -20C. The reaction was
removed from the cooling bath and concentrated. The
residue was dissolved in DCM and washed with water,
dried and concentrated. The residue was puriﬁed by ﬂash
chromatography in Tol-Me2CO 5–30% to give 0.344 g of
the target product 2 (0.43 mmol; 40%) (supplementary
materials).
Compound 4 (Fig. 1c): A solution of the protected
thiophosphate 2 (0.12 g, 0.15 mmol) in a mixture of DCM
(3 ml) and triethylamine (0.75 ml) was kept at RT for
24 h. The reaction mixture was concentrated and dried
in vacuum to give crude glycosyl thiophosphate (2a),
(supplementary materials).
To a stirred slurry of uridine 50-monophosphate bis-tri-
ethylammonium salt (0.076 g, 0.144 mmol) in a mixture of
anhydrous MeCN (0.6 ml), N, N-dimethylaniline (0.070 ml,
0.56 mmol) and Et3N (0.04 ml, 0.288 mmol), a solution
of triﬂuoroacetic anhydride (0.12 ml, 0.864 mmol) in
MeCN (0.2 ml) was added via capillary at 0C. The reaction
mixture was stirred for a few minutes at RT, while clear
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Fig. 1 Design, synthesis and inhibitory properties of hOGT substrate/
product analogues. a Chemical structures of UDP–GlcNAc, the
substrate of hOGT, the substrate analogues UDP-C-GlcNAc and
UDP-S-GlcNAc, the hOGT product UDP and the analogue C-UDP
and alloxan. The atoms in the uracil moiety are numbered. Alloxan
ring atoms are numbered according to the uracil numbering system.
b Dose–response curves of the inhibitors with hOGT. The transfer of
GlcNAc from UDP–GlcNAc onto a peptide [DEBtide (Blair et al.
manuscript submitted)] by hOGT was assayed in presence of
increasing concentrations of UDP-S-GlcNAc, UDP-C-GlcNAc,
alloxan and C-UDP. The remaining activity is plotted against the
inhibitor concentration. Data were ﬁtted using the standard IC50
equation in the GraFit program (Leatherbarrow 2001). c Reagents and
conditions for UDP-S-GlcNAc synthesis: (i) Bis(9H-ﬂuoren-9-
ylmethyl)-diisopropylamidophosphite, 1H-tetrazole, MeCN, RT,
30 min; then dimethyldioxirane, -40Ct o-20C, 30 min; (ii)
DCM:Et3N (4:1), RT, 24 h; (iii) (a) 2a 1 3, MeCN, RT, 16 h; (b)
MeOH:H2O:Et3N (5:2:1), RT, 16 h; followed by size exclusion
chromatography
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123yellowish solution was formed and concentrated to remove
excess of triﬂuoroacetic anhydride. The yellow oily residue
was re-dissolved in MeCN (0.5 ml) and cooled to 0C. A
solution of N-methylimidazole (0.057 ml, 0.72 mmol) and
Et3N (0.12 ml, 0.864 mmol) in anhydrous MeCN (0.2 ml)
was then added to the above solution via capillary. The
reaction mixture was further stirred for 15 min at RT. The
prepared solution of UMP-N-methylimidazolide (3) was
added via capillary to a ﬂask containing a solution of
the crude product 2a in MeCN (0.8 ml)at 0C. The resulting
turbid yellow solution was further stirred overnight at RT.
The reaction was quenched by addition of cold Et3NHHCO3
buffer (1 ml) and stirred for 20 min. The reaction was con-
centrated; the residue was dissolved in a mixture of
MeOH:H2O:Et3N (5:2:1, 8 ml) and kept at RT for 16 h. The
reaction mixture was concentrated, diluted with water, and
extracted with DCM. The layers were separated and the
aqueous phase was additionally extracted with DCM. The
aqueous layer was concentrated to give yellowish oily resi-
due. This was puriﬁed by size exclusion chromatography
(Bio-Gel P2 ﬁne; column 2.6 9 100 cm; ﬂow rate 0.4 ml/
min; elution with 0.25 M NH4HCO3). The fractions
containing the product were pooled and evaporated. The
residue was re-dissolved in water and freeze dried to give
0.0216 g (0.012 mmol, 22%) of the target product 4 (95%
purity by
1H NMR) as ﬂuffy white solid (supplementary
materials).
UDP-C-GlcNAc and C-UDP analogues were synthes-
ised as described previously (Clarke et al. 2008; Borodkin
et al., manuscript submitted). Alloxan was purchased from
Sigma–Aldrich.
Results and discussion
Design and synthesis of substrate/product analogues
as potential OGT inhibitors
In the absence of potent, cell permeable OGT inhibitors we
decided to explore substrate analogues as potential inhibitor
scaffolds.Weaimed toinvestigate UDP–GlcNAcanalogues
as hOGT inhibitors, in which the glycosidic oxygen would
be replaced with non-hydrolysible isosteric linkages con-
ferringstabilitytowardsenzymaticandchemicalhydrolysis.
Recent studies have described the synthesis and evaluation
ofa UDP-GlcNAc glycosyl C-phosphonate analogue (UDP-
C-GlcNAc, Fig. 1a) against O-GlcNAc transferases of dif-
ferent origin (Clarke et al. 2008; Chang et al. 2006). Inter-
estingly, UDP-C-GlcNAc did not show any inhibitory
activity against hOGT (Hajduch et al. 2008), potentially
indicating an essential role of the glycosidic oxygen atom in
substrate binding. It is possible that the lack of hydrogen
bonds between the isosteric, albeit non-isopolar, methylene
group of the glycosyl C-phosphonate explains why UDP-C-
GlcNAc is a weak hOGT inhibitor.
In a search for novel non-hydrolysable UDP–GlcNAc
congeners with enhanced biological activity proﬁles, a
thioglycosyl (thiophosphate) analogue of UDP–GlcNAc
(UDP-S-GlcNAc, Fig. 1a) was envisaged as a possible
target. Replacement of the glycosyl oxygen with the sul-
phur atom would give rise to an analogue, which despite
not being isosteric (van der Waals radius of sulphur is
1.85 A ˚ compared to 1.44 A ˚ for oxygen) would still bear
more resemblance to the natural O-linked substrate than the
glycosyl C-phosphonate analogue. This non-hydrolysable
substrate analogue might further reveal insight into the
binding mode of UDP–GlcNAc, since the previously
reported XcOGT–UDP-C-GlcNAc complex (Clarke et al.
2008) revealed a substrate binding site which is not fully
compatible with catalysis of larger nucleotide–sugar ana-
logues that were reported previously (Gross et al. 2005;
Laughlin and Bertozzi 2009).
No thiophosphate analogues of nucleotide diphosphate
sugars have so far been synthesised, except for an anomeric
sulphur analogue of CMP-Neu5Ac (Cohen and Halcomb
2000). This unique compound was found to be surprisingly
hydrolytically stable compared to the natural O-linked
substrate and two orders of magnitude poorer substrate for
a-2,3-sialyl transferase than the natural O-linked substrate
(Cohen and Halcomb 2000). No evidence of a perceptible
inhibition of the sialyl transferase activity with this com-
pound was reported.
We envisioned that the UDP-S-GlcNAc (Fig. 1a) could
be prepared by coupling of suitably protected GlcNAc
glycosyl thiophosphate and activated 50-uridine mono-
phosphate by analogy with the common practice of pyro-
phosphate bond construction in the chemical synthesis of
nucleoside diphosphate sugars. Initially, GlcNAc diallyl-
thiophosphate (not shown) was prepared from the a-con-
ﬁgured GlcNAc glycosyl thiol 1 (Fig. 1c) as a potential
precursor of GlcNAc glycosyl thiophosphate according to
the published procedure (Knapp and Myers 2001). How-
ever, all attempts to liberate thiophosphate functionality by
removing allyl groups from this compound using tetrakis
(triphenylphosphine) palladium catalyst in the presence of
various allyl cation scavengers were utterly unsuccessful,
leading predominantly to the formation of dephosphoryl-
ated products. Seeking for an alternative solution, we
suggested that change of the thiophosphate protecting
groups to 9-ﬂuorenylmethyl would allow the deprotection
in mild anhydrous conditions. Thus, the glycosyl thiol 1
(Fig. 1c) was S-phosphitylated with bis(9H-ﬂuoren-9-
ylmethyl)-diisopropylamidophosphite (Bialy and Wald-
mann 2004) followed by oxidation with dimethyldioxirane
to give the GlcNAc bis-9-ﬂuorenylmethyl glycosyl thio-
phosphate 2 (Fig. 1c) in acceptable yield (
31P; d 23.36).
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in DCM for 24 h produced the requisite glycosyl thio-
phosphate 2a (Fig. 1c) as judged by
31P NMR spectrum,
showing the presence of the single phosphorous containing
product (
31P; d 13.06). The crude glycosyl thiophosphate
was then reacted with UMP-N-methylimidazolide 3
(Fig. 1c; Marlow and Kiessling 2001) to furnish the target
molecule in moderate yield after deprotection and puriﬁ-
cation by gel ﬁltration chromatography. Formation of the
pyrophosphate bond was evident from the presence of
typical pair of doublets d 5.10 and -11.97 (JP,P0 = 29 Hz)
in the
31P spectrum of compound 4.
To investigate the inhibition of UDP–GlcNAc and UDP
analogues, kinetic studies were carried out using recom-
binant hOGT protein. A synthetic peptide (DEBtide) was
used as the acceptor substrate. The incorporation of [
3H]-
GlcNAc from [
3H]-UDP–GlcNAc was monitored using a
newly developed radioactive assay (Blair et al. manuscript
submitted). The Km for UDP–GlcNAc was determined to
be 1 lM, in agreement to the Km determined previously
(Haltiwanger et al. 1992). In our hands, hOGT displays
product inhibition with UDP (IC50 of 1.8 lM, Fig. 1a). We
therefore also decided to explore the inhibition proﬁle of a
non-hydrolysible a,b-methylene bisphosphonate analogue
with the pyrophosphate oxygen replaced by a methylene
group (C-UDP).
Synthesis of C-UDP was performed using published
procedures (Borodkin et al., manuscript submitted).
UDP-S-GlcNAc—a sub-millimolar inhibitor of hOGT
and substrate binding probe
Using the glycosyltransferase assay with a model acceptor
peptide, UDP-S-GlcNAc appears to inhibit hOGT with an
IC50 of 93 lM (Fig. 1b; Table 1), similar to the previously
described weak hOGT inhibitor UDP-C-GlcNAc (Clarke
et al. 2008; Hajduch et al. 2008) (IC50 = 41 lM, Fig. 1b;
Table 1). Human OGT has so far resisted expression and
puriﬁcation to levels required for structural studies and
biophysical measurement of ligand afﬁnity. To further
study the binding mode of the novel UDP–GlcNAc ana-
logues, we therefore used the apparent hOGT homologue
from Xanthomonas campestris pv. campestris (XcOGT) for
which structural data and protein crystals suitable for
soaking studies are available (Clarke et al. 2008; Martinez-
Fleites et al. 2008). SPR experiments with recombinant and
puriﬁed XcOGT protein revealed that UDP has a binding
afﬁnity (Kd) of 112 lM for XcOGT (Table 2), which
should be compared to inhibition with IC50 = 1.8 lMo f
hOGT activity (Tables 1, 2). The micromolar hOGT
inhibitors UDP-S-GlcNAc and UDP-C-GlcNAc both bind
XcOGT weakly, with a Kd[1 mM (Table 2). UDP–Glc-
NAc itself binds to XcOGT weakly with a Kd of approxi-
mately 15 mM (Table 2). We next investigated whether
UDP-S-GlcNAc is a substrate for hOGT or XcOGT.
Kinetic experiments using recombinant hOGT/XcOGT
and protein acceptor substrates in conjunction with a
general O-GlcNAc antibody did not show any evidence for
O-GlcNAcylation. Furthermore, a colorimetric assay with
the thio-reactive reagent DTNB [5,50-dithio-bis(2-nitro-
benzoic acid)], and a ﬂuorescent assay with N-(1-pyrene)
maleimide did not shown any hydrolysis of UDP-S-
GlcNAc by hOGT or XcOGT.
To investigate the binding mode of the UDP-S-GlcNAc
substrate analogue, XcOGT protein crystals were soaked
with the compound. Collection of synchrotron diffraction
data and subsequent reﬁnement yielded a ﬁnal model with
statistics shown in Table 3. UDP-S-GlcNAc binds in the
active site of XcOGT (Fig. 2a). The uracil moiety occupies
a pocket formed by Lys441 to His444, whilst stacking with
the side chain of Tyr447 (Fig. 2a). The uracil moiety is
involved in a total of three hydrogen bonds with the pro-
tein, with the backbone of Leu442/Pro443 and the His444
side chain (Fig. 2a). The ribose moiety of UDP-S-GlcNAc
makes a hydrogen bond with Asp471 (Fig. 2), a side chain
that is conserved in OGTs from organisms across the
evolutionary spectrum. Recent studies reported that a
mutant of the equivalent position in hOGT (Asp925) is no
longer able to O-GlcNAcylate an acceptor substrate
(Clarke et al. 2008; Martinez-Fleites et al. 2008). SPR
measurements show that the D471A-XcOGT mutant no
longer binds UDP–GlcNAc (Table 2).
Surprisingly, a structural comparison with the previ-
ously described UDP-C-GlcNAc complex (Clarke et al.
2008) shows that while the uridine moiety occupies a
similar position in both complexes (maximum atom
shift = 0.8 A ˚), the sugar and phosphate moieties occupy
different binding sites (Fig. 2a). The UDP-S-GlcNAc
phosphate mimics occupy a groove, interacting with the
side chains of Lys388 (Lys842 in hOGT) and Asn385
Table 1 Inhibition data of the hOGT substrate/product analogues
Compound IC50 [lM]
a BEI
b
UDP 1.8 ± 1.0 15
C-UDP 9.0 ± 1.0 13
UDP-C-GlcNAc 41 ± 77
UDP-S-GlcNAc 93 ± 15 7
Alloxan 18 ± 13 4
a The dose–response experiments were performed with a UDP-
GlcNAc concentration tenfold below the Km
b Binding efﬁciency index (Abad-Zapatero and Metz 2005),
BEI =- log(Ki)/M, with M being the mass in kDa and Ki is derived
from IC50 data using the Cheng and Prusoff equation with
[S] = 125 nM and Km = 1 lM. Cheng–Prusoff equation: Ki = IC50/
1 ? ([S]/Km)
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123[Gln839 in hOGT, mutation of which inactivates the
enzyme (Clarke et al. 2008; Martinez-Fleites et al. 2008)].
The sugar moiety occupies a position above the pyro-
phosphate, hydrogen bonding with His218 and Arg137
(Fig. 2a). In contrast to the previously described UDP-C-
GlcNAc–XcOGT crystallographic complex (Clarke et al.
2008), this binding mode is compatible with the reported
tolerance of hOGT for larger substitutions on the N-acetyl
group (Gross et al. 2005; Laughlin and Bertozzi 2009),
and also exposes the b-face of the anomeric carbon for
nucleophilic attack (Fig. 2a). Loss of activity in hOGT
His558 mutants (His218 in XcOGT) has been proposed to
reﬂect a role as a general base in the reaction mechanism
(Martinez-Fleites et al. 2008), which would be incompati-
ble with the UDP-S-GlcNAc conformation described here
(Fig. 2a). Similarly, Cys917 (Tyr463 in XcOGT) has been
proposed to be the catalytic base to activate the peptide
substrate, but is not in proximity to the GlcNAc anomeric
carbon in the UDP-S-GlcNAc complex. Interestingly, the
complex shows that the hydroxyl group of Tyr387 is
positioned within 4.5 A ˚ from the anomeric carbon. This
Tyr387 is conserved amongst XcOGT and hOGT (Fig. 2a;
Clarke et al. 2008) and is in close proximity to Lys388,
which could prime the tyrosine to act as a base to activate
the acceptor substrate. However, the identity of the hOGT
catalytic machinery remains to be ﬁrmly established.
The a,b-methylene bisphosphonate UDP
is a micromolar hOGT inhibitor
We have found that the a,b-methylene bisphosphonate
UDP analogue (C-UDP) appears to inhibit hOGT with an
IC50 of 9 lM (Table 1; Fig. 1b). The binding afﬁnity of
C-UDP to XcOGT was investigated by SPR experiments,
revealing a Kd of 530 lM (Table 2). This binding constant
is approximately ﬁvefold weaker than for UDP, but in
agreement with the ranking observed for hOGT inhibition
(Tables 1, 2).
We determined the crystal structure of the XcOGT–
C-UDP complex to investigate the molecular basis of the
weaker hOGT inhibition and XcOGT binding compared
Table 2 Dissociation constant (Kd) of compounds for XcOGT-WT
from SPR experiments
Compound Kd (mM)
WT-XcOGT D471A-XcOGT
UDP 0.110 ± 0.001 n.b.
C-UDP 0.530 ± 0.006 n.b.
UDP-GlcNAc 15.1 ± 0.5 n.b.
UDP-S-GlcNAc [1 [1
UDP-C-GlcNAc [1 [1
Alloxan [1 n.d.
n.b. = no binding
n.d. = not determined
Table 3 Details of data
collection and structure
reﬁnement for UDP-S-GlcNAc,
C-UDP and alloxan bound to
XcOGT
Values within brackets are for
the highest resolution shell. All
measured data were included in
structure reﬁnement
XcOGT–UDP-S-
GlcNAc
XcOGT–C-UDP XcOGT–alloxan
Space group P212121 P212121 P212121
Unit cell (A ˚)a = 83.7 a = 84.3 a = 83.5
b = 100.0 b = 95.0 b = 100.0
c = 155.5 c = 157.7 c = 157.2
Resolution range (A ˚) 30.00–2.60
(2.69–2.60)
30.00–2.40
(2.46–2.40)
30.00–2.55
(2.64–2.55)
# Observed reﬂections 181,565 170,621 171,199
# Unique reﬂections 37,400 (3,453) 47,424 (2,347) 42,658 (4,136)
Redundancy 4.9 (4.9) 3.6 (3.2) 4.0 (3.9)
I/rI 32.5 (2.9) 13.6 (2.15) 16.3 (2.1)
Completeness (%) 91.7 (86.4) 92.9 (70.1) 97.8 (96.7)
Rmerge 0.061 (0.691) 0.067 (0.543) 0.048 (0.438)
R, Rfree 23.9, 27.7 24.4, 30.4 25.4, 29.7
RMSD from ideal geometry
Bonds (A ˚) 0.01 0.01 0.02
Angles () 1.5 1.4 1.5
B-factor RMSD (backbone bonds)
\B[(A ˚ 2)
0.5 0.5 0.5
Protein 73.4 45.0 75.6
Ligand 78.7 38.2 71.7
Solvent 66.6 48.1 72.1
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123to UDP (Fig. 2b). The uracil ring of C-UDP interacts
with the XcOGT protein via the same three hydrogen
bonds and p–p stacking interactions as observed for the
UDP-S-GlcNAc complex vide supra (Fig. 2a, b). The key
hydrogen bond of the ribose with Asp471 is also con-
served. In agreement with this, SPR measurements with
the XcOGT-D471A mutant revealed that neither UDP
nor C-UDP bind to the mutant enzyme (Table 2).
Interestingly, however, the a,b-phosphonates are shifted
(maximum atomic shift = 1.4 A ˚) compared to the
previously published XcOGT–UDP complex (Martinez-
Fleites et al. 2008). While Asn385 and Lys388 still
hydrogen bond the phosphonates (albeit with swapped
interactors compared to the XcOGT–UDP-S-GlcNAc
complex; Fig. 2a), no hydrogen bonds between the
b-phosphonate and Thr468/Lys388 are present (4.5 and
3.7 A ˚, respectively) as a result of the methylene-induced
positional shift of the b-phosphonate. However, an
additional hydrogen bond is introduced between Tyr468
and the b-phosphonate. This could explain the lower
inhibition constant of C-UDP in comparison to UDP
(Table 1).
Alloxan mimics the uracil binding mode
in the XcOGT structure
The ﬁrst hOGT inhibitor described was the uracil
derivative alloxan (Konrad et al. 2002; Fig. 1a). It was
proposed that alloxan inhibits hOGT through covalent
modiﬁcation of cysteine residues (Konrad et al. 2002). In
our assay, alloxan is a low micromolar inhibitor of
hOGT (IC50 of 18 lM) compared to the previously
reported IC50 of 100 lM (Konrad et al. 2002). It is
revealing to express the average contribution per atom to
the DG of binding [the so-called binding efﬁciency index
(BEI) (Abad-Zapatero and Metz 2005)] for the hOGT
inhibitors (Table 1). Interestingly, even though the small
compound alloxan is a weaker inhibitor of hOGT than
UDP and C-UDP, however, in absolute terms, in terms
of ligand efﬁciency alloxan is a more efﬁcient binder
(BEI of 34) than UDP and C-UDP (BEI of 15 and 13,
respectively). Thus, these data indicate that alloxan,
although chemically unstable, may be a very efﬁcient
fragment to probe the hOGT uracil-binding site, perhaps
as a moiety or as part of a large inhibitor molecule. To
allow such inhibitors to be developed, we attempted to
obtain an XcOGT–alloxan complex. XcOGT crystals
were soaked with alloxan and data were collected to
2.55 A ˚ (Table 3). Well-deﬁned electron density for
alloxan is located in the uracil pocket, with the com-
pound mimicking the previously described XcOGT–uracil
interactions (Fig. 2c). The C2 and C4/C6-carbonyl
groups (numbering system according to Fig. 1a) accept
hydrogen bonds from the side chain nitrogen of His444
and the backbone nitrogen atom of Leu442, respectively
(Fig. 2c). A third hydrogen bond is formed between the
alloxan N1/N3 and the backbone carbonyl of Leu442.
p–p stacking interactions are observed with the aromatic
side chain of Tyr447 (His901 in hOGT). Previous work
has described an ‘active site lid’ (Clarke et al. 2008) that
controls access to the donor binding site—this loop is
observed to be in the ‘closed’ conformation in the
alloxan complex. There is no evidence to support the
recent hypothesis that alloxan covalently modiﬁes active
site cysteine residues (Konrad et al. 2002). Unexpec-
tedly, SPR experiments carried out with XcOGT revealed
a weak binding constant of alloxan to XcOGT
(Kd[1 mM). It is possible that alloxan degraded to
alloxanic acid over the course of the experiment, but it
should also be noted that the two substrate analogues
reported here showed signiﬁcantly weaker binding to
XcOGT than their observed inhibition of hOGT.
Concluding remarks
In the search for novel hOGT inhibitors, we have focus-
sed our work on the synthesis and evaluation of novel
hOGT substrate and product analogues (Fig. 1). The
inhibitory potency of these compounds revealed that they
are all sub-millimolar inhibitors of hOGT (Table 1).
Structural data obtained from UDP-S-GlcNAc soaking
experiments with XcOGT crystals revealed a competitive
binding mode, yet different from the previously published
UDP-C-GlcNAc complex (Clarke et al. 2008). The sugar
Fig. 2 X-ray crystallographic determination of inhibitor binding
modes. a Stereo ﬁgure of XcOGT in complex with UDP-S-GlcNAc
and superposition of the previously described XcOGT–UDP-C-
GlcNAc complex [PDB entry 2JLB (Clarke et al. 2008)]. XcOGT
active site residues are shown in sticks with grey carbon, red oxygen,
blue nitrogen atoms. UDP-S-GlcNAc and UDP-C-GlcNAc are shown
with green and purple carbon, respectively. Hydrogen bonds for the
XcOGT–UDP-S-GlcNAc complex are indicated by black dashed
lines. Unbiased |Fo|-|Fc|, /calc electron density map (2.75r) is shown
as cyan chickenwire. b Stereo ﬁgure of XcOGT in complex with
C-UDP compared to the UDP complex [PDB entry 2VSN (Martinez-
Fleites et al. 2008)]. XcOGT active site residues are shown in sticks
with grey carbon, red oxygen, blue nitrogen atoms (transparent sticks
for XcOGT–UDP), ligands shown in green carbon atoms. Active site
residues involved in hydrogen bonds are labelled. Hydrogen bonds
are indicated by black dashed lines. Unbiased |Fo|-|Fc|, /calc electron
density map (2.25r) is shown as cyan chickenwire. c Stereo ﬁgure of
XcOGT in complex with alloxan. XcOGT active site are shown in
sticks with green carbon, red oxygen, blue nitrogen atoms in the
active site of XcOGT (sticks with grey carbon atoms). Hydrogen
bonds are indicated by black dashed lines. Unbiased |Fo|-|Fc|, /calc
electron density map (2.25r) is shown as cyan chickenwire. Black
dashed lines showing hydrogen bonds for XcOGT–alloxan complex
b
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123moiety projects above the diphosphate group mimic
positioning the thioglycosidic bond within hydrogen
bonding distance of Asn385, which might play a role in
catalysis [mutation of the equivalent Gln839 in hOGT
generates an inactive species (Clarke et al. 2008; Marti-
nez-Fleites et al. 2008)]. This could be similar to the role
of Gln189 in LgtC, a retaining galactosyltransferase from
Neisseria meningitidis (Tvaroska 2004). On the basis of
structural, biochemical and molecular modelling, Gln189
in LgtC was predicted to be involved in hydrogen bond
formation with the donor and the acceptor in the transi-
tion state (Tvaroska 2004). However, the identity of the
catalytic base in hOGT remains to be ﬁrmly established.
To further investigate the reduced inhibitory effects of
the potent UDP analogue, we determined the crystallo-
graphic complex of XcOGT–C-UDP. A hydrogen bond
network, similar to the previously reported XcOGT–UDP
complex, was observed, however, conformational changes
for the b-phosphonate result in elimination of two hydro-
gen bonds which could explain the lower inhibition con-
stant of C-UDP in comparison to UDP (Table 1). Structural
and kinetic studies with alloxan, an unspeciﬁc hOGT
inhibitor, have shown that this small molecule is an efﬁ-
cient fragment to inhibit hOGT. Chemical modiﬁcations of
this compound (i.e. of the C5/C6-carbonyl groups) can be
explored with the help of the binding mode revealed by the
structural data presented here.
The novel substrate/product analogue hOGT inhibitors
were also tested in cell-based assays, but failed to induce
an observable decrease in global O-GlcNAcylation levels.
Despite C-UDP being a potent hOGT inhibitor, this
nucleotide analogue is a hydrophilic and negatively
charged compound that might not be cell permeable. Thus,
it remains to be explored whether modiﬁed (e.g. esteriﬁed)
derivatives of C-UDP would be more cell permeable.
Finally, it should be noted that all compounds considered
in this study may be equally potent inhibitors of other
glycosyltransferases using UDP–GlcNAc as the donor (e.g.
in N-linked glycosylation), or enzymes involved in sugar
nucleotide biosynthesis. It is anticipated that the structural
data for the compounds reported here could aid the rational
design of more potent and selective substrate/product
analogue OGT inhibitors.
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